Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
BCDA On Other Exchanges
Symbol
Exchange
NASDAQ GM
All times are local (Market data is delayed by at least 15 minutes).

biocardia inc (BCDA) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
11.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOCARDIA INC (BCDA)

Related News

No related news articles were found.

biocardia inc (BCDA) Related Businessweek News

No Related Businessweek News Found

biocardia inc (BCDA) Details

BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. The company offers the Helix biotherapeutic delivery system product line that offers a catheter system for the local delivery of cells, gene, and protein therapeutics to the heart; and the Morph vascular access product line, which offers catheter products for interventional medicine. Its lead therapeutic candidate is the CardiAMP Cell Therapy System that is in Phase III pivotal trial for ischemic systolic heart failure. The CardiAMP Cell Therapy System comprises cell potency screening test, a point of care cell processing platform, and a biotherapeutic delivery system. BioCardia, Inc. is also developing CardiALLO Cell Therapy System, which is an allogeneic mesenchymal stem cell-based product candidate from universal donors for use in multiple unrelated patients. The company was formerly known as BioCardia DeviceCo, Inc. and changed its name to BioCardia, Inc. in August 2002. BioCardia, Inc. was incorporated in 2002 and is based in San Carlos, California.

30 Employees
Last Reported Date: 07/13/15
Founded in 2002

biocardia inc (BCDA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: --
Chief Financial Officer
Total Annual Compensation: --
Vice President of Operations
Total Annual Compensation: --
Vice President of Clinical & Regulatory Affai...
Total Annual Compensation: --
Director of Research and Development
Total Annual Compensation: --
Compensation as of Fiscal Year 2015.

biocardia inc (BCDA) Key Developments

BioCardia Seeks Acquisitions

BioCardia, Inc. has filed an IPO in the amount of $57.50 million. BioCardia said, "We also may use a portion of the net proceeds to acquire complementary businesses, products, services or technologies. The amount and timing of these expenditures will vary depending on a number of factors, including competitive and technological developments and the rate of growth, if any, of our business."

BioCardia, Inc. Auditor Raises 'Going Concern' Doubt

BioCardia, Inc. filed its Annual on Jun 16, 2015 for the period ending Dec 31, 2014. In this report its auditor, KPMG LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

BioCardia, Inc. Announces FDA Acceptance of Phase III Clinical Trial Protocol Studying Bone Marrow-Derived Cell Therapy for Heart Failure Patients

BioCardia, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company's application to begin a Phase III clinical trial of its bone marrow-derived CardiAMP Therapy for heart failure. The clinical trial is a randomized, controlled, multi-center study of 250 patients evaluating CardiAMP Therapy at up to 40 clinical sites. The CardiAMP Therapy for heart failure integrates a proprietary biomarker panel to identify candidates likely to respond to therapy, a cell processing system consisting of a proprietary, high-dosage formulation of autologous bone marrow-derived cells and a unique transendocardial delivery system that ensures efficient and consistent targeted delivery. This therapy will be reviewed under the PMA regulations by the FDA's Center for Biologics Evaluation and Research (CBER) division. The CardiAMP trial efficacy endpoints include improvements in functional capacity as measured by the Six Minute Walk Test, quality of life as measured by the Minnesota Living with Heart Failure Questionnaire, and survival. Safety endpoints include non-inferiority with respect to survival and freedom from major adverse cardiac events. Studies supporting the CardiAMP Therapy including the Phase I Transendocardial Autologous Bone Marrow in Myocardial Infarction Study, which was published in Eurointervention, and the Phase I/II Transendocardial Autologous Cells in Heart Failure Trial, which was published in the Journal of the American Medical Association (JAMA) - showed statistically and clinically significant results. Trial results have demonstrated an excellent safety profile, as well as functional and quality of life improvements.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCDA:US $0.00 USD 0.00

BCDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BCDA.
View Industry Companies
 

Industry Analysis

BCDA

Industry Average

Valuation BCDA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCARDIA INC, please visit www.biocardia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.